PROCEPT BioRobotics Corporation (PRCT)
PRCT trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1588978/000158897826000009/0001588978-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRCT on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001588978 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $308.1M |
| Net income | -$95.6M |
| Operating income | -$103.9M |
| Net margin | -31.0% |
| Operating margin | -33.7% |
| Revenue growth | +37.2% |
| Cash | $286.5M |
| Total assets | $508.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $218.4M cash; operating cash flow -$19.2M a quarter. | Report 2026-09-30 |
| Shares outstanding | 57,536,121 (2026-10-29); 55,878,589 a year earlier; 50,498,621 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, San Jose, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $11.0M, sold $616K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $98.3M | -$26.5M | -$9.0M | $218.4M | $51.8M | $352.3M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $94.5M | -$26.9M | -$19.3M | $227.9M | $51.7M | $337.3M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $83.1M | -$31.6M | -$38.1M | $245.6M | $51.7M | $322.0M | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $76.4M | -$29.8M | -$10.3M | $286.5M | $51.6M | $308.1M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $83.3M | -$21.4M | -$6.6M | $294.3M | $51.6M | $299.9M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $79.2M | -$19.6M | -$15.0M | $302.7M | $51.5M | $274.9M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $69.2M | -$24.7M | -$17.0M | $316.2M | $51.5M | $249.1M | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $68.2M | -$18.9M | -$32.4M | $333.7M | $51.5M | $224.5M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-10-30 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 399 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +15.4% |
| 1 month | +24.6% |
| 3 months | +8.4% |
| Year to date | -24.3% |
| 1 year | -21.8% |
| From 52-week high | -34.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVCR | NovoCure Limited | $11.30 | -4.48% | $1.3B |
| TNDM | Tandem Diabetes Care Inc. | $18.48 | -7.92% | $1.3B |
| DRTS | Alpha Tau Medical Ltd. | $11.97 | -10.54% | $1.1B |
| KMTS | Kestra Medical Technologies Ltd. | $27.97 | -2.34% | $1.7B |
| IART | Integra LifeSciences Holdings Corporation | $13.98 | -2.92% | $1.1B |
| IRMD | iRadimed Corporation | $84.84 | -0.60% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| INSP | Inspire Medical Systems Inc. | $59.12 | -3.24% | $1.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier